The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.

Cabozantinib significantly improved progression free survival in patients with pNET ... well-differentiated pancreatic neuroendocrine tumors (pNET) and well-differentiated extra-pancreatic ...

By inhibiting IL-5 signaling, mepolizumab reduces the production and survival of eosinophils ... belzutifan would be the first available therapy in the US for these rare neuroendocrine tumors. The ...

Based on the phase 3 CABINET trial, the FDA approved Cabometyx for some patients with previously treated neuroendocrine ...

The FDA has approved Cabometyx for some patients 12 years old and older with previously treated neuroendocrine tumors.

When it came to the study’s secondary endpoints of survival, Telix pointed to a median overall survival (OS) rate of 12.4 ...

Both the use of next-generation sequencing (NGS) testing for cancer and the rate of claim denials for such testing increased ...

Neoadjuvant combination immunotherapy may improve survival compared with single-agent therapy for patients with head and neck ...

During a live event, Megan Kruse, MD, discussed NCCN guidelines and key therapies for patients with HR-positive metastatic ...

Where federal tax brackets and rates will land next year depends whether Congress extends the 2017 tax cuts for individuals that expire at year-end. That law kept the former seven brackets ...